Cellectis Statistics
Total Valuation
Cellectis has a market cap or net worth of $89.44 million. The enterprise value is $5.07 million.
| Market Cap | 89.44M |
| Enterprise Value | 5.07M |
Important Dates
The next estimated earnings date is Tuesday, November 10, 2026, after market close.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cellectis has 72.70 million shares outstanding. The number of shares has increased by 0.22% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 72.70M |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 2.12% |
| Owned by Institutions (%) | 18.75% |
| Float | 48.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.40 |
| Forward PS | 0.92 |
| PB Ratio | 2.18 |
| P/TBV Ratio | 2.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.08 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.37, with a Debt / Equity ratio of 1.96.
| Current Ratio | 1.37 |
| Quick Ratio | 1.34 |
| Debt / Equity | 1.96 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.18 |
Financial Efficiency
Return on equity (ROE) is -94.54% and return on invested capital (ROIC) is -23.43%.
| Return on Equity (ROE) | -94.54% |
| Return on Assets (ROA) | -11.67% |
| Return on Invested Capital (ROIC) | -23.43% |
| Return on Capital Employed (ROCE) | -43.80% |
| Weighted Average Cost of Capital (WACC) | 14.44% |
| Revenue Per Employee | $278,703 |
| Profits Per Employee | -$285,214 |
| Employee Count | 229 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -351,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.32% in the last 52 weeks. The beta is 2.91, so Cellectis's price volatility has been higher than the market average.
| Beta (5Y) | 2.91 |
| 52-Week Price Change | -67.32% |
| 50-Day Moving Average | 1.94 |
| 200-Day Moving Average | 3.09 |
| Relative Strength Index (RSI) | 41.46 |
| Average Volume (20 Days) | 110,150 |
Short Selling Information
The latest short interest is 320,614, so 0.58% of the outstanding shares have been sold short.
| Short Interest | 320,614 |
| Short Previous Month | 351,327 |
| Short % of Shares Out | 0.58% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.06 |
Income Statement
In the last 12 months, Cellectis had revenue of $63.82 million and -$65.31 million in losses. Loss per share was -$0.64.
| Revenue | 63.82M |
| Gross Profit | 63.82M |
| Operating Income | -58.00M |
| Pretax Income | -65.67M |
| Net Income | -65.31M |
| EBITDA | -46.68M |
| EBIT | -58.00M |
| Loss Per Share | -$0.64 |
Balance Sheet
The company has $166.69 million in cash and $80.35 million in debt, with a net cash position of $86.34 million or $1.19 per share.
| Cash & Cash Equivalents | 166.69M |
| Total Debt | 80.35M |
| Net Cash | 86.34M |
| Net Cash Per Share | $1.19 |
| Equity (Book Value) | 41.07M |
| Book Value Per Share | 0.56 |
| Working Capital | 49.46M |
Cash Flow
In the last 12 months, operating cash flow was -$41.63 million and capital expenditures -$2.18 million, giving a free cash flow of -$43.80 million.
| Operating Cash Flow | -41.63M |
| Capital Expenditures | -2.18M |
| Depreciation & Amortization | 11.32M |
| Net Borrowing | -16.36M |
| Free Cash Flow | -43.80M |
| FCF Per Share | -$0.60 |
Margins
Gross margin is 100.00%, with operating and profit margins of -90.87% and -102.34%.
| Gross Margin | 100.00% |
| Operating Margin | -90.87% |
| Pretax Margin | -102.89% |
| Profit Margin | -102.34% |
| EBITDA Margin | -73.14% |
| EBIT Margin | -90.87% |
| FCF Margin | n/a |
Dividends & Yields
Cellectis does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.22% |
| Shareholder Yield | -0.22% |
| Earnings Yield | -54.46% |
| FCF Yield | -48.97% |
Analyst Forecast
The average price target for Cellectis is $4.83, which is 312.82% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.83 |
| Price Target Difference | 312.82% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -20.99% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cellectis has an Altman Z-Score of -1.16 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.16 |
| Piotroski F-Score | 2 |